APA (7th ed.) Citation

Zhu, F., Huang, T., Jin, P., Zhang, L., Jin, Z., Zhang, W., . . . Xie, L. Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. MDPI AG.

Chicago Style (17th ed.) Citation

Zhu, Fengcai, et al. Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. MDPI AG.

MLA (9th ed.) Citation

Zhu, Fengcai, et al. Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. MDPI AG.